Literature DB >> 18574846

Impact of preoperative thyroid ultrasonography on the surgical management of primary hyperparathyroidism.

D P Monroe1, B S Edeiken-Monroe, J E Lee, D B Evans, N D Perrier.   

Abstract

BACKGROUND: Primary hyperparathyroidism (PHPT) with coexisting thyroid disease has been considered a contraindication to minimally invasive parathyroidectomy (MIP). This study assessed the impact of thyroid ultrasonography and guided fine-needle aspiration (FNA) biopsy with cytological review of the aspiration in distinguishing patients eligible for MIP from those requiring open parathyroidectomy with thyroid surgery.
METHODS: The records of 194 consecutive patients who had minimally invasive or open parathyroidectomy for sporadic PHPT were reviewed retrospectively. Thyroid ultrasonographic findings and FNA results were compared with surgical and pathology records.
RESULTS: A total of 163 patients (84.0 per cent) were eligible for MIP based on ultrasonographic findings with or without FNA results. Ultrasonography detected concurrent thyroid disease in 163 patients (84.0 per cent). Thirty-nine (23.9 per cent) underwent FNA, of whom 16 had benign findings and were eligible for MIP; the remaining 23 had suspicious FNA results and had open parathyroidectomy combined with thyroid surgery. Postoperative thyroid histopathology confirmed malignancy in nine patients, eight of whom had disease detected ultrasonographically. Micronodular thyroid disease (less than 1 cm) accounted for four of nine malignancies.
CONCLUSION: Most patients with PHPT are eligible for MIP. Experienced ultrasonographers can diagnose coexisting micronodular and macronodular thyroid disease, and identify patients eligible for MIP. (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18574846     DOI: 10.1002/bjs.6097

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  8 in total

1.  Impact of thyroid nodular disease on 99mTc-sestamibi scintigraphy in patients with primary hyperparathyroidism.

Authors:  Joaquin Gómez-Ramírez; Juan Jose Sancho-Insenser; Jose Antonio Pereira; Jaime Jimeno; Assumpta Munné; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2010-07-14       Impact factor: 3.445

2.  Co-existent thyroid disease in patients treated for primary hyperparathyroidism: implications for clinical management.

Authors:  S Ryan; D Courtney; C Timon
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-15       Impact factor: 2.503

3.  Surgical management of primary hyperparathyroidism.

Authors:  Stephen Ryan; Danielle Courtney; Julia Moriariu; Conrad Timon
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-10-16       Impact factor: 2.503

4.  Concomitant thyroid disease and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy.

Authors:  Marie-Christine Wright; Kelly Jensen; Hossam Mohamed; Carolyn Drake; Khuzema Mohsin; Dominique Monlezun; Nuha Alsaleh; Emad Kandil
Journal:  Gland Surg       Date:  2017-08

5.  Surgical treatment of concomitant thyroid and parathyroid disorders: analysis of 4882 cases.

Authors:  Milan D Jovanovic; Vladan R Zivaljevic; Aleksandar D Diklic; Branislav R Rovcanin; Goran V Zoric; Ivan R Paunovic
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-09-12       Impact factor: 2.503

6.  Benign and Malignant Thyroid Gland Diseases in the Patients with Primary Hyperparathyroidism.

Authors:  Mehmet Celik; Sibel Guldiken; Semra Ayturk; Buket Yilmaz Bulbul; Ebru Tastekin; Nuray Can; Atakan Sezer; Funda Ustun; Ahmet Kucukarda
Journal:  Int J Appl Basic Med Res       Date:  2017 Apr-Jun

7.  Impact of concomitant thyroid pathology on preoperative workup for primary hyperparathyroidism.

Authors:  Oleg Heizmann; C T Viehl; R Schmid; J Müller-Brand; B Müller; D Oertli
Journal:  Eur J Med Res       Date:  2009-01-28       Impact factor: 2.175

8.  Accessing the influence of 99mTc-Sesta-MIBI-positive thyroid nodules on preoperative localisation studies in patients with primary hyperparathyroidism.

Authors:  Lindsay Hargitai; Maria Schefner; Tatjana Traub-Weidinger; Alexander Haug; Melisa Arikan; Christian Scheuba; Philipp Riss
Journal:  Langenbecks Arch Surg       Date:  2022-01-21       Impact factor: 2.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.